Risk for Second Primary Cancer May Be No Higher With CAR T-Cell Versus Standard of Care
THURSDAY, Sept. 12, 2024 (HealthDay News) -- The overall second primary malignancy (SPM) point estimate was 5.8 percent for patients receiving chimeric antigen receptor (CAR) T-cell therapy...